Artificial Intelligence Is The Real Thing For Pharma And Medtech

Artificial intelligence might seem more the preserve of computer nerds and tech giants than pharma companies. But according to Boehringer Ingelheim's global chief data scientist, Philipp Diesinger, "the entire industry is looking at data science and AI". This increased focus on data could drastically change the way drugs are developed and paid for. For example, AI will be vital if outcomes-based healthcare is to be successfully implemented, pointed out Philips' chief innovation & strategy officer, Jeroen Tas, who also stressed that AI really signaled a new way of handling data. He described AI as "the way you interpret data. You constantly stream the data and add that data to the body of knowledge," he told EP Vantage during the AI Summit in London in May.